by rvvadmin | Jul 25, 2022 | 2022
TORONTO, July 25, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
by rvvadmin | Jun 24, 2022 | 2022
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, June 24, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...
by rvvadmin | Jun 6, 2022 | 2022
The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, June 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
by rvvadmin | May 31, 2022 | 2022
WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for...
by rvvadmin | May 26, 2022 | 2022
The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...
by rvvadmin | May 16, 2022 | 2022
The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA TORONTO, May 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences...
